Advertisement

Topics

Moderate-to-Severe Plaque Psoriasis - Biotech, Pharma and Life Science Channel

02:08 EDT 24th October 2017 | BioPortfolio

Psoriasis is a chronic, immune disease that affects the skin. It occurs when the immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis affects up to 1.8 million people in the UK,ix approximately 20 percent of whom have moderate-to-severe plaque psoriasis.Psoriasis can occur on any part of the body and is associated with other serious health conditions, such as diabetes and heart disease. The most common form of psoriasis, plaque psoriasis, appears as raised, red patches covered with a silvery white buildup of dead skin cells.

News Articles [90 Associated News Articles listed on BioPortfolio]

Global and Regional States Cytotoxic Drug Market Research Report 2017 [Report Updated: 21102017] Prices from USD $3500

SummaryCytotoxic drugs inhibit or prevent the function of cells. Cytotoxic drugs are primarily used to treat cancer, frequently as part of a chemotherapy regime. Recently, their uses have expanded to ...

North America Injectable Drug Delivery Market Industry Trends and Forecast to 2024 [Report Updated: 01072017] Prices from USD $4200

Synopsis: North America injectable drug delivery market is expected to reach USD 354.5 billion by 2024 from USD 154.0 billion in 2016, at a CAGR of 11.0% in the forecast period 2017 to 2024. The repor...

Can-Fite Issued Patent in Korea for Piclidenoson in the Treatment of Psoriasis

Can-Fite has distribution agreements in Korea for Piclidenoson and Namodenoson Piclidenoson slated to enter Phase III study in treatment of psor...

Clarify Medical and DermatologistOnCall Announce a Partnership to Innovate the Treatment of Chronic Skin Conditions

-- Chronic Skincare Innovator and Leading Online Dermatology Provider Join Forces to Bring Revolutionary New Treatment Option to Patients Suffering from Psoriasis, Vitiligo and Ec...

Psoriasis Pipeline Review, H2 2017 [Report Updated: 19092017] Prices from USD $2500

Psoriasis Pipeline Review, H2 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Psoriasis Pipeline Review, H2 2017, provides an overview of the Psoriasis...

Psoriatic Arthritis' Impact Not Always Visible or Understood, Patients Say

PHILADELPHIA, PA--(Marketwired - October 12, 2017) - Explaining the "invisible" aspects of psoriatic arthritis often presents a challenge, according to "Psoriatic Arthritis In America," a newly releas...

MC2 Therapeutics A/S Announces First Patient Dosed in Pivotal US Phase 3 Trial in Psoriasis Vulgaris

First patient dosed in the pivotal Phase 3 trial assessing the safety and efficacy of MC2-01 Cream in US Topline results are expected in Q3 2018 Copenhagen, Denmark, October 11, 2017 / B3C ne...

AnaptysBio Inc ANAB Financial and Strategic SWOT Analysis Review [Report Updated: 13092017] Prices from USD $125

AnaptysBio Inc ANAB Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalDat...

Thync Pilot Study Demonstrates First Effective Use of Bioelectronics to Treat Psoriasis

LOS GATOS, Calif., Oct. 4, 2017 /PRNewswire/ -- Thync Global Inc., a bioelectronics company, today reported positive results from a pilot study evaluating the use of its proprietary neuromodulation te...

Global and Regional Specialty Drug Distribution Market Research Report 2017 [Report Updated: 21092017] Prices from USD $3500

SummarySpecialty Drug Distribution is a link of pharmaceutical logistics; it distributes Specialty Drug to consumers relying on certain logistics equipment, technology and logistics management informa...

Events [0 Results]

None

Companies [22 Associated Companies listed on BioPortfolio]

Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion d...

Arrien Pharmaceuticals

Arrien Pharmaceuticals is a targeted therapeutics drug discovery and development company. Arrien applies its proprietary fragment-based FIELDS drug discovery technology to targ...

Tiziana Life Sciences plc

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. The C...

Santalis Pharmaceuticals, Inc.

Santalis Pharmaceuticals, Inc. is a wholly-owned subsidiary of TFS Corporation, Ltd. (ASX: TFC). Santalis, and its sister company, ViroXis, were acquired by TFS in July 2015 and a...

Ziarco Pharma Ltd.

Ziarco is a clinical-stage biotechnology company developing innovative therapeutics targeting dermatological and inflammatory diseases. ZPL-389, the Company’s lead compound, ...

Akaal Pharma Pty Ltd.

Akaal Pharma Pty Ltd (Akaal Pharma) is a clinical-stage drug discovery and development company focused on the development of novel small molecule drugs for the treatment of inflam...

Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells...

Shape Pharmaceuticals, Inc.

Shape Pharmaceuticals, Inc. is developing SHP-141, a novel, topical, “soft-drug” HDAC inhibitor for the treatment of patients with cutaneous T cell lymphoma (CTCL) and p...

Helmedix Pty Ltd

Helmedix is developing new therapies for autoimmune diseases. The company has identified peptides derived from helminthic worms that have immune-modulating properties. These peptides are being explo...

HealOr

Founded in 2002, HealOr is a privately owned, clinical-stage specialty biopharmaceutical company developing a first-in-class pipeline of topical therapeutics to treat a variety of...

Clinical Trials [560 Associated Clinical Trials listed on BioPortfolio]

Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis

This is a multicenter, randomized, double-blind, positive drug parallel-group controlled clinical study in China to evaluate efficacy, safety, tolerability and immunogenicity of HLX03 and ...

A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream

This trial is a randomized, investigator-blind, multicentre, vehicle- and comparator-controlled, parallel-group trial with the purpose of evaluating efficacy, safety and convenience of the...

This Study is Designed to See if AZD0284 is Effective in Treating Plaque Psoriasis and Whether it Causes Any Side Effects.

The Sponsor is developing the study drug, AZD0284, for the potential treatment of Plaque psoriasis. Psoriasis is a skin condition that causes red, flaky, crusty patches of skin covered wit...

Secukinumab Therapy for the Treatment of Moderate to Severe Plaque Psoriasis With Response Monitoring Using Optical Coherence Tomography (OCT).

This is a phase IV, single-center, open label, single arm study in which a group of 30 subjects with moderate to severe plaque psoriasis will receive secukinumab therapy. Non-invasive imag...

Role of Chemokine and Chemokine Receptor in Psoriasis

This study aims to elucidate the role of Chemokine and chemokine receptor in the pathogenesis of Psoriasis by using human psoriasis skin xenograft SCID mouse model. The hypothesis is that ...

Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Plaque Psoriasis

This is an open-label, safety study designed to assess the multiple-dose pharmacokinetics and potential for adrenal suppression following topical treatment with halobetasol propionate 0.05...

Post-Marketing Surveillance Study of OTEZLA

To evaluate the safety and efficacy of OTEZLA in actual clinical settings of use in patients with Psoriasis vulgaris that is with an inadequate response to topical therapies and Psoriasis ...

This Study Has 2 Parts. The First Part Tests How Healthy Men Tolerate Different Doses of BI 730357 and How the Metabolism of Midazolam is Affected by BI 730357. The Second Part is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI

Part 1 of this trial is a Phase Ib evaluation of the safety, tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) properties of Multiple Rising Dose (MRD) administration of BI 73...

Efficacy and Safety of Xenogenic AD-MSCs With Moderate to Severe Psoriasis

The purpose of this study is to evaluate the efficacy and safety of Adipose Derived Mesenchymal Stem Cells (AD-MSCs) with moderate to severe psoriasis. Any adverse events related to AD-MSC...

Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic Nail Disease

Nail psoriasis has a high incidence amongst patients with psoriasis.It is estimated to affect 80% of psoriatic patients at some time during their lives and has a significant adverse influe...

PubMed Articles [319 Associated PubMed Articles listed on BioPortfolio]

Pushing the Envelope in Psoriasis: Late Cornified Envelope Proteins Possess Antimicrobial Activity.

Deletion of late cornified envelope (LCE) genes LCE3B and LCE3C (LCE3B/C-del) is a psoriasis risk factor linked to the major psoriasis risk gene HLA-C*06. Niehues et al. demonstrate that LCE3B/C-del ...

Apremilast for the treatment of moderate to severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study.

Palmoplantar psoriasis is a variant of psoriasis vulgaris which can severely impair quality of life.

Stem Cells as Potential Candidates for Psoriasis Cell-Replacement Therapy.

Recent years have seen considerable progress in explaining the mechanisms of the pathogenesis of psoriasis, with a significant role played in it by the hyper-reactivity of Th1 and Th17 cells, Treg fun...

Endothelial function is impaired in the cutaneous microcirculation of adults with psoriasis through reductions in nitric oxide-dependent vasodilation.

Psoriasis is an independent risk factor for cardiovascular disease, however the underlying mechanisms are not fully understood. Deficits in conduit arterial function are evident in psoriatics, but pot...

A molecular basis of human T cell receptor autoreactivity toward self-phospholipids.

Human T cell autoreactivity toward lipid antigens presented by CD1 proteins can manifest in numerous diseases, including psoriasis, contact hypersensitivities, and allergies. However, the molecular me...

Commentary on Long-Pulsed Nd: YAG Laser Treatment for Nail Psoriasis.

Anti-psoriatic and toxicity evaluation of methotrexate chitin nanogel in imiquimod induced mice model.

Methotrexate loaded chitin nanogel (MCNG) was formulated for its topical use in psoriasis. MCNG was characterized by DLS, TEM and FTIR. The MCNG particles were spherical in shape with size of 196±14n...

Microbe-dependent induction of IL-9 by CLA(+) T cells in psoriasis and relationship with IL-17A.

IL-9 is present in psoriatic lesions and produced by lymphocytes. However, it is not known whether this cytokine is induced by relevant pathogenic triggers of psoriasis, such as Streptococcus pyogenes...

Risk of Serious Infection in Patients with Psoriasis on Biologic Therapies: a Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Serious infection is a concern for patients with psoriasis on biologic therapies. We assessed the risk of serious infections of biologics used to treat psoriasis by comparison with a cohort on non-bio...

Visceral Adiposity in Psoriasis is Associated With Vascular Inflammation by (18)Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Beyond Cardiometabolic Disease Risk Factors in an Observational Cohort Study.

We sought to examine the relationship between visceral adipose tissue (VAT) and vascular inflammation (VI) by (18)fluorodeoxyglucose ((18)FDG) positron-emission tomography (PET)/computed tomography (...

Videos

None available.

Medical and Biotech [MESH] Definitions

A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.

A topical anti-inflammatory glucocorticoid used in DERMATOSES, skin allergies, PSORIASIS, etc.

A glucocorticoid used topically in the treatment of DERMATITIS; ECZEMA; or PSORIASIS. It may cause skin irritation.

An anthracene derivative that disrupts MITOCHONDRIA function and structure and is used for the treatment of DERMATOSES, especially PSORIASIS. It may cause FOLLICULITIS.

A humanized monoclonal antibody that binds to IL-12 and IL-23 and is used as a DERMATOLOGIC AGENT in the treatment of patients with plaque PSORIASIS who have not responded to other therapies.

Quick Search
Advertisement
 

Relevant Topics

Psoriasis
Psoriasis is a common skin condition affecting 2-3% of the population of the United Kingdom, where the skins replacement process is sped taking 2-6 days instead of the usual 21 - 28 days for the replacement of skin cells. Patients experience an accumulat...

Wound management
Anything that breaks the skin is a wound because when the skin is broken, there's a risk of germs getting into the body and causing an infection. Follow and track Wound Care News on BioPortfolio: Wound Car...

review and buy Moderate-to-Severe Plaque Psoriasis market research data and corporate reports here

Channels Quicklinks